#USA #Class Action #San Francisco #Securities Fraud #PROCEPT BioRobotics

Understanding the PROCEPT BioRobotics Class Action

In the realm of securities investments, timely information is vital for making informed decisions. Recently, investors in PROCEPT BioRobotics Corporation (NASDAQ: PRCT) have been alerted by Hagens Berman Sobol Shapiro LLP regarding the filing of a class action lawsuit. The suit has garnered attention due to significant losses experienced by shareholders amid allegations of misleading practices surrounding the company’s sales of its single-use handpiece, a key component of its Aquablation therapy for prostate treatment.

What You Need to Know About the Lawsuit

The class action lawsuit focuses on the period between February 28, 2024, and February 25, 2026, during which time substantial discrepancies in PROCEPT's financial disclosures became apparent. Allegedly, the company misrepresented its sales practices, particularly regarding its encouraging of customers to place bulk orders through extensive discount programs. This practice seems to have artificially inflated sales figures while ultimately harming future revenue expectations.

According to the lawsuit, the misleading communications from the company's executives about sales reports contributed to a false representation of PROCEPT's financial health. Investors who acquired PROCEPT shares during this time may have been misled about the company’s operational and financial conditions.

Timeline of Events

Multiple key disclosures led to a rapid decline in PROCEPT's stock price:
1. August 6, 2025: The company announced its Q2 results with handpiece sales significantly failing to meet consensus estimates, prompting immediate concern among investors.
2. November 4, 2025: Another quarterly report revealed similar discrepancies, and during the earnings call, management acknowledged not managing customer inventory effectively.
3. February 25, 2026: For the first time, PROCEPT disclosed detailed data about its procedures in the field, revealing a shocking excess inventory of handpieces that had accumulated beyond what was necessary for actual usage, resulting in a staggering 30% decline in sequential sales.

These events contributed to a serious drop in stock value, with shares declining over 48% from their earlier valuations.

Importance of the Investigation

Hagens Berman is dedicated to uncovering the truth behind PROCEPT's financial practices and determining whether there was any deliberate intent to mislead investors. Reed Kathrein, a partner at the firm leading the investigation, emphasizes the need to assess whether the company has adequately informed its investors about its business operations, particularly regarding handpiece sales.

This investigation not only aims to hold PROCEPT accountable but also provides a call to action for investors who have been adversely affected. Those with substantial losses are encouraged to submit their information and possibly participate in the legal proceedings to reclaim their investments.

Next Steps for Investors

If you have faced significant losses by investing in PROCEPT during the class action period, it's crucial to act by the deadline of September 22, 2026, to join the lead plaintiff in the lawsuit. Hagens Berman advises shareholders to gather documentation of their losses and connect with their attorneys for assistance in this potentially impactful case.

Ultimately, this situation serves as a reminder of the volatility within stock markets and the importance of vigilance when tracking corporate disclosures. By participating, investors not only seek to recover losses but also contribute to enhancing corporate accountability in the financial landscape. For further details, visit Hagens Berman's website for updates on the investigation and class action.